Holen Sie sich die Stockscreener-App
120.56
10.42%
11.38
Vorhandelsmarkt:
126.50
5.94
+4.93%
Schlusskurs vom Vortag:
$109.18
Offen:
$110.08
24-Stunden-Volumen:
363.88K
Relative Volume:
4.91
Marktkapitalisierung:
$4.21B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.61M
KGV:
-102.67
EPS:
-1.1742
Netto-Cashflow:
-
1W Leistung:
+3.29%
1M Leistung:
+31.04%
6M Leistung:
+79.16%
1J Leistung:
+46.22%
1-Tages-Spanne:
$108.00
$121.89
1-Wochen-Bereich:
$105.88
$125.24
52-Wochen-Spanne:
$49.00
$125.24
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLTE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
120.56 | 3.81B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Mizuho | Neutral |
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Belite Bio (NASDAQ:BLTE) Earns Neutral Rating from Analysts at Mizuho - Defense World
Belite Bio’s Stock Dips Amid Analyst Caution - TipRanks
Mizuho initiates Belite Bio stock coverage with Neutral rating ahead of key trial data - Investing.com Canada
Will Belite Bio Inc Depositary Receipt stock sustain high P E ratiosTrade Exit Summary & Consistent Return Investment Signals - newser.com
Belite Bio stock reaches all-time high at 125.0 USD By Investing.com - Investing.com South Africa
Belite Bio stock reaches all-time high at 125.0 USD - Investing.com
Belite Bio ADR’s Earnings Call: Progress Amid Rising Costs - MSN
Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
(BLTE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Belite Bio (NASDAQ:BLTE) Cut to Sell at Wall Street Zen - Defense World
Using data tools to time your Belite Bio Inc Depositary Receipt exitBear Alert & Real-Time Volume Surge Alerts - newser.com
Promising Outlook for Belite Bio’s Tinlarebant Drives Buy Rating Amidst Strong Financial Position and Regulatory Support - TipRanks
Belite Bio Advances in Retinal Disease Therapeutics - MSN
Belite Bio (NASDAQ:BLTE) Stock Price Down 8.2% Following Weak Earnings - Defense World
Why Belite Bio Inc (Common Stock) (D01) stock is listed among top recommendationsJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Belite Bio reports Q3 EPS (65c), consensus (49c) - TipRanks
Belite Bio Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Belite Bio Q3 2025 reports increased R&D expenses - Investing.com India
Belite Bio, Inc. ADR Shares Surge Amid Trial Success - TipRanks
Belite Bio stock reaches all-time high at 117.95 USD By Investing.com - Investing.com Canada
Belite Bio stock reaches all-time high at 117.95 USD - Investing.com
Earnings Flash (BLTE) Belite Bio Posts Q3 Net Loss $0.65 a Share, vs. FactSet Est. of $0.45 Loss - MarketScreener
Belite Bio Announces Q3 2025 Results and Key Trial Progress - TipRanks
Belite Bio Q3 net loss widens on higher R&D expenses - MarketScreener
Belite Bio (NASDAQ: BLTE) NMPA, MHRA accept Tinlarebant; closes $125M private placement - Stock Titan
Belite Bio (BLTE) to Release Quarterly Earnings on Monday - Defense World
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to ... - Black Hills Pioneer
Understanding Belite Bio Inc Depositary Receipt’s price movementJobs Report & Technical Pattern Based Buy Signals - newser.com
Belite Bio (BLTE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Exact Sciences (EXAS) Gets a Buy from Benchmark Co. - The Globe and Mail
Analyzing Belite Bio Inc Depositary Receipt with multi timeframe chartsWeekly Market Outlook & Low Volatility Stock Suggestions - newser.com
Cash per share of Belite Bio, Inc. ADR – SWB:D01 - TradingView
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference 2025, Nov-04-2025 10 - MarketScreener
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025Slideshow - Seeking Alpha
Belite Bio (NASDAQ:BLTE) Stock Price Up 7.3% Following Analyst Upgrade - MarketBeat
Belite Bio (NASDAQ:BLTE) Hits New 52-Week HighShould You Buy? - MarketBeat
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results - GlobeNewswire
Belite Bio Recieves UK Acceptance for Conditional Approval of Stargardt Disease Drug - MarketScreener
Belite Bio (NASDAQ: BLTE) to host third-quarter results webcast at 4:30 p.m. ET - Stock Titan
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of... - markets.businessinsider.com
Belite Bio Announces UK’s Medicines and Healthcare Products - GlobeNewswire
MHRA Agrees to Accept CMA for Tinlarebant — Belite Bio (BLTE); DRAGON topline Q4 2025 - Stock Titan
Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat
Belite Bio stock hits all-time high at 101.92 USD By Investing.com - Investing.com Australia
Belite Bio stock hits all-time high at 101.92 USD - Investing.com
Can machine learning forecast Belite Bio Inc Depositary Receipt recoveryIndex Update & Consistent Growth Equity Picks - newser.com
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
Benchmark Co. Reaffirms Their Hold Rating on NeoGenomics (NEO) - The Globe and Mail
How Belite Bio Inc Depositary Receipt stock performs during Fed tightening cyclesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Belite Bio to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference November 4th - GlobeNewswire
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference - GlobeNewswire
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):